nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—EGFR—adrenal gland cancer	0.422	0.767	CbGaD
Bosutinib—ABCB1—adrenal gland cancer	0.128	0.233	CbGaD
Bosutinib—Vandetanib—EGFR—adrenal gland cancer	0.00217	0.447	CrCbGaD
Bosutinib—Gefitinib—EGFR—adrenal gland cancer	0.00206	0.424	CrCbGaD
Bosutinib—CLK3—cardiac atrium—adrenal gland cancer	0.000965	0.00556	CbGeAlD
Bosutinib—STK25—adrenal cortex—adrenal gland cancer	0.000962	0.00554	CbGeAlD
Bosutinib—HIPK4—gonad—adrenal gland cancer	0.000955	0.0055	CbGeAlD
Bosutinib—DSTYK—pituitary gland—adrenal gland cancer	0.000942	0.00543	CbGeAlD
Bosutinib—PLK2—adrenal cortex—adrenal gland cancer	0.000936	0.00539	CbGeAlD
Bosutinib—EIF2AK1—cardiac atrium—adrenal gland cancer	0.000933	0.00537	CbGeAlD
Bosutinib—EIF2AK1—pituitary gland—adrenal gland cancer	0.000911	0.00525	CbGeAlD
Bosutinib—TLK1—adrenal gland—adrenal gland cancer	0.00091	0.00524	CbGeAlD
Bosutinib—VRK2—cardiac atrium—adrenal gland cancer	0.000904	0.00521	CbGeAlD
Bosutinib—PRKCQ—adrenal gland—adrenal gland cancer	0.000897	0.00517	CbGeAlD
Bosutinib—STK33—adrenal gland—adrenal gland cancer	0.000885	0.0051	CbGeAlD
Bosutinib—VRK2—pituitary gland—adrenal gland cancer	0.000883	0.00509	CbGeAlD
Bosutinib—STK26—gonad—adrenal gland cancer	0.000871	0.00502	CbGeAlD
Bosutinib—TNIK—pituitary gland—adrenal gland cancer	0.000866	0.00499	CbGeAlD
Bosutinib—SYK—pituitary gland—adrenal gland cancer	0.000866	0.00499	CbGeAlD
Bosutinib—STK26—pituitary gland—adrenal gland cancer	0.00085	0.0049	CbGeAlD
Bosutinib—CLK3—adrenal gland—adrenal gland cancer	0.000842	0.00485	CbGeAlD
Bosutinib—DSTYK—adrenal gland—adrenal gland cancer	0.000842	0.00485	CbGeAlD
Bosutinib—BMX—adrenal gland—adrenal gland cancer	0.000842	0.00485	CbGeAlD
Bosutinib—WEE1—gonad—adrenal gland cancer	0.000835	0.00481	CbGeAlD
Bosutinib—WEE1—cardiac atrium—adrenal gland cancer	0.000834	0.0048	CbGeAlD
Bosutinib—DMPK—cardiac atrium—adrenal gland cancer	0.000834	0.0048	CbGeAlD
Bosutinib—BLK—adrenal gland—adrenal gland cancer	0.000832	0.0048	CbGeAlD
Bosutinib—PHKG1—adrenal gland—adrenal gland cancer	0.000823	0.00474	CbGeAlD
Bosutinib—CASK—adrenal gland—adrenal gland cancer	0.000823	0.00474	CbGeAlD
Bosutinib—CHEK2—pituitary gland—adrenal gland cancer	0.000821	0.00473	CbGeAlD
Bosutinib—DMPK—pituitary gland—adrenal gland cancer	0.000814	0.00469	CbGeAlD
Bosutinib—WEE1—pituitary gland—adrenal gland cancer	0.000814	0.00469	CbGeAlD
Bosutinib—EIF2AK1—adrenal gland—adrenal gland cancer	0.000814	0.00469	CbGeAlD
Bosutinib—TXK—adrenal gland—adrenal gland cancer	0.000797	0.00459	CbGeAlD
Bosutinib—STK25—gonad—adrenal gland cancer	0.000797	0.00459	CbGeAlD
Bosutinib—STK25—cardiac atrium—adrenal gland cancer	0.000796	0.00459	CbGeAlD
Bosutinib—STK3—adrenal cortex—adrenal gland cancer	0.00079	0.00455	CbGeAlD
Bosutinib—FES—adrenal gland—adrenal gland cancer	0.000789	0.00455	CbGeAlD
Bosutinib—VRK2—adrenal gland—adrenal gland cancer	0.000789	0.00455	CbGeAlD
Bosutinib—STK25—pituitary gland—adrenal gland cancer	0.000777	0.00448	CbGeAlD
Bosutinib—PLK2—gonad—adrenal gland cancer	0.000775	0.00446	CbGeAlD
Bosutinib—PLK2—cardiac atrium—adrenal gland cancer	0.000774	0.00446	CbGeAlD
Bosutinib—TNIK—adrenal gland—adrenal gland cancer	0.000774	0.00446	CbGeAlD
Bosutinib—SYK—adrenal gland—adrenal gland cancer	0.000774	0.00446	CbGeAlD
Bosutinib—SIK3—gonad—adrenal gland cancer	0.00077	0.00443	CbGeAlD
Bosutinib—SIK3—cardiac atrium—adrenal gland cancer	0.000769	0.00443	CbGeAlD
Bosutinib—CDK2—adrenal gland—adrenal gland cancer	0.000766	0.00442	CbGeAlD
Bosutinib—STK26—adrenal gland—adrenal gland cancer	0.000759	0.00438	CbGeAlD
Bosutinib—PLK2—pituitary gland—adrenal gland cancer	0.000756	0.00436	CbGeAlD
Bosutinib—STK36—adrenal cortex—adrenal gland cancer	0.000752	0.00433	CbGeAlD
Bosutinib—MERTK—adrenal cortex—adrenal gland cancer	0.000743	0.00428	CbGeAlD
Bosutinib—CHEK2—adrenal gland—adrenal gland cancer	0.000733	0.00423	CbGeAlD
Bosutinib—CAMK1D—cardiac atrium—adrenal gland cancer	0.000731	0.00421	CbGeAlD
Bosutinib—DMPK—adrenal gland—adrenal gland cancer	0.000727	0.00419	CbGeAlD
Bosutinib—WEE1—adrenal gland—adrenal gland cancer	0.000727	0.00419	CbGeAlD
Bosutinib—BCR—adrenal cortex—adrenal gland cancer	0.000724	0.00417	CbGeAlD
Bosutinib—MAP3K12—adrenal cortex—adrenal gland cancer	0.000719	0.00414	CbGeAlD
Bosutinib—CAMK1D—pituitary gland—adrenal gland cancer	0.000714	0.00412	CbGeAlD
Bosutinib—STK24—pituitary gland—adrenal gland cancer	0.000706	0.00407	CbGeAlD
Bosutinib—FER—gonad—adrenal gland cancer	0.0007	0.00403	CbGeAlD
Bosutinib—TYRO3—gonad—adrenal gland cancer	0.0007	0.00403	CbGeAlD
Bosutinib—CSK—adrenal cortex—adrenal gland cancer	0.0007	0.00403	CbGeAlD
Bosutinib—FER—cardiac atrium—adrenal gland cancer	0.000699	0.00403	CbGeAlD
Bosutinib—CSNK1A1—adrenal cortex—adrenal gland cancer	0.000695	0.004	CbGeAlD
Bosutinib—STK25—adrenal gland—adrenal gland cancer	0.000695	0.004	CbGeAlD
Bosutinib—HCK—adrenal cortex—adrenal gland cancer	0.000691	0.00398	CbGeAlD
Bosutinib—CLK1—adrenal cortex—adrenal gland cancer	0.000691	0.00398	CbGeAlD
Bosutinib—EPHA3—adrenal gland—adrenal gland cancer	0.00069	0.00397	CbGeAlD
Bosutinib—ALK—pituitary gland—adrenal gland cancer	0.000683	0.00394	CbGeAlD
Bosutinib—FER—pituitary gland—adrenal gland cancer	0.000683	0.00394	CbGeAlD
Bosutinib—EPHA5—pituitary gland—adrenal gland cancer	0.000683	0.00394	CbGeAlD
Bosutinib—PLK2—adrenal gland—adrenal gland cancer	0.000675	0.00389	CbGeAlD
Bosutinib—SIK3—adrenal gland—adrenal gland cancer	0.000671	0.00387	CbGeAlD
Bosutinib—BTK—pituitary gland—adrenal gland cancer	0.000666	0.00384	CbGeAlD
Bosutinib—ERBB4—cardiac atrium—adrenal gland cancer	0.000654	0.00377	CbGeAlD
Bosutinib—MAP4K2—pituitary gland—adrenal gland cancer	0.000647	0.00373	CbGeAlD
Bosutinib—ROCK1—gonad—adrenal gland cancer	0.000646	0.00372	CbGeAlD
Bosutinib—STK4—adrenal gland—adrenal gland cancer	0.000646	0.00372	CbGeAlD
Bosutinib—CSNK1E—adrenal cortex—adrenal gland cancer	0.000644	0.00371	CbGeAlD
Bosutinib—STK3—pituitary gland—adrenal gland cancer	0.000638	0.00368	CbGeAlD
Bosutinib—ERBB4—pituitary gland—adrenal gland cancer	0.000638	0.00368	CbGeAlD
Bosutinib—CAMK1D—adrenal gland—adrenal gland cancer	0.000638	0.00368	CbGeAlD
Bosutinib—IRAK4—adrenal cortex—adrenal gland cancer	0.000634	0.00365	CbGeAlD
Bosutinib—STK24—adrenal gland—adrenal gland cancer	0.000631	0.00363	CbGeAlD
Bosutinib—BMPR2—cardiac atrium—adrenal gland cancer	0.000627	0.00361	CbGeAlD
Bosutinib—Gefitinib—ABCB1—adrenal gland cancer	0.000626	0.129	CrCbGaD
Bosutinib—STK36—gonad—adrenal gland cancer	0.000622	0.00359	CbGeAlD
Bosutinib—ULK3—adrenal cortex—adrenal gland cancer	0.00062	0.00357	CbGeAlD
Bosutinib—BMPR2—pituitary gland—adrenal gland cancer	0.000612	0.00353	CbGeAlD
Bosutinib—FER—adrenal gland—adrenal gland cancer	0.00061	0.00352	CbGeAlD
Bosutinib—MAP3K7—adrenal cortex—adrenal gland cancer	0.00061	0.00351	CbGeAlD
Bosutinib—STK36—pituitary gland—adrenal gland cancer	0.000607	0.0035	CbGeAlD
Bosutinib—MAP4K4—gonad—adrenal gland cancer	0.000604	0.00348	CbGeAlD
Bosutinib—MAP4K4—cardiac atrium—adrenal gland cancer	0.000603	0.00348	CbGeAlD
Bosutinib—TBK1—adrenal cortex—adrenal gland cancer	0.000603	0.00347	CbGeAlD
Bosutinib—MERTK—pituitary gland—adrenal gland cancer	0.0006	0.00346	CbGeAlD
Bosutinib—BCR—gonad—adrenal gland cancer	0.0006	0.00345	CbGeAlD
Bosutinib—BCR—cardiac atrium—adrenal gland cancer	0.000599	0.00345	CbGeAlD
Bosutinib—MAP4K1—adrenal gland—adrenal gland cancer	0.000598	0.00344	CbGeAlD
Bosutinib—MAP3K12—gonad—adrenal gland cancer	0.000595	0.00343	CbGeAlD
Bosutinib—BTK—adrenal gland—adrenal gland cancer	0.000595	0.00343	CbGeAlD
Bosutinib—MAP3K12—cardiac atrium—adrenal gland cancer	0.000595	0.00343	CbGeAlD
Bosutinib—MAP4K4—pituitary gland—adrenal gland cancer	0.000589	0.0034	CbGeAlD
Bosutinib—TNK2—adrenal gland—adrenal gland cancer	0.000586	0.00338	CbGeAlD
Bosutinib—BCR—pituitary gland—adrenal gland cancer	0.000585	0.00337	CbGeAlD
Bosutinib—NUAK2—pituitary gland—adrenal gland cancer	0.000585	0.00337	CbGeAlD
Bosutinib—MAP2K1—gonad—adrenal gland cancer	0.000583	0.00336	CbGeAlD
Bosutinib—STK35—gonad—adrenal gland cancer	0.000583	0.00336	CbGeAlD
Bosutinib—STK35—cardiac atrium—adrenal gland cancer	0.000583	0.00336	CbGeAlD
Bosutinib—MAP3K12—pituitary gland—adrenal gland cancer	0.000581	0.00335	CbGeAlD
Bosutinib—RPS6KB1—adrenal cortex—adrenal gland cancer	0.00058	0.00334	CbGeAlD
Bosutinib—CSK—gonad—adrenal gland cancer	0.000579	0.00334	CbGeAlD
Bosutinib—CSK—cardiac atrium—adrenal gland cancer	0.000579	0.00333	CbGeAlD
Bosutinib—MAP4K2—adrenal gland—adrenal gland cancer	0.000578	0.00333	CbGeAlD
Bosutinib—CSNK1A1—gonad—adrenal gland cancer	0.000576	0.00332	CbGeAlD
Bosutinib—CSNK1A1—cardiac atrium—adrenal gland cancer	0.000575	0.00331	CbGeAlD
Bosutinib—AXL—adrenal cortex—adrenal gland cancer	0.000574	0.00331	CbGeAlD
Bosutinib—CLK1—gonad—adrenal gland cancer	0.000572	0.0033	CbGeAlD
Bosutinib—CLK1—cardiac atrium—adrenal gland cancer	0.000571	0.00329	CbGeAlD
Bosutinib—STK3—adrenal gland—adrenal gland cancer	0.00057	0.00329	CbGeAlD
Bosutinib—CSK—pituitary gland—adrenal gland cancer	0.000565	0.00326	CbGeAlD
Bosutinib—CSNK1A1—pituitary gland—adrenal gland cancer	0.000562	0.00324	CbGeAlD
Bosutinib—BMP2K—gonad—adrenal gland cancer	0.000561	0.00324	CbGeAlD
Bosutinib—HCK—pituitary gland—adrenal gland cancer	0.000558	0.00322	CbGeAlD
Bosutinib—CLK1—pituitary gland—adrenal gland cancer	0.000558	0.00322	CbGeAlD
Bosutinib—LRRK2—gonad—adrenal gland cancer	0.000556	0.00321	CbGeAlD
Bosutinib—ABL2—pituitary gland—adrenal gland cancer	0.000555	0.0032	CbGeAlD
Bosutinib—SLK—adrenal cortex—adrenal gland cancer	0.000553	0.00318	CbGeAlD
Bosutinib—CYP3A4—urine—adrenal gland cancer	0.000549	0.00316	CbGeAlD
Bosutinib—EPHB4—adrenal cortex—adrenal gland cancer	0.000549	0.00316	CbGeAlD
Bosutinib—CAMK2G—pituitary gland—adrenal gland cancer	0.000548	0.00316	CbGeAlD
Bosutinib—BMPR2—adrenal gland—adrenal gland cancer	0.000547	0.00315	CbGeAlD
Bosutinib—LRRK2—pituitary gland—adrenal gland cancer	0.000543	0.00313	CbGeAlD
Bosutinib—STK36—adrenal gland—adrenal gland cancer	0.000543	0.00313	CbGeAlD
Bosutinib—EPHB3—adrenal gland—adrenal gland cancer	0.000543	0.00313	CbGeAlD
Bosutinib—PTK2B—gonad—adrenal gland cancer	0.000542	0.00312	CbGeAlD
Bosutinib—EPHA2—adrenal cortex—adrenal gland cancer	0.000538	0.0031	CbGeAlD
Bosutinib—MERTK—adrenal gland—adrenal gland cancer	0.000536	0.00309	CbGeAlD
Bosutinib—MAP4K4—adrenal gland—adrenal gland cancer	0.000526	0.00303	CbGeAlD
Bosutinib—SIK1—gonad—adrenal gland cancer	0.000525	0.00303	CbGeAlD
Bosutinib—MAP3K3—adrenal cortex—adrenal gland cancer	0.000525	0.00303	CbGeAlD
Bosutinib—SIK1—cardiac atrium—adrenal gland cancer	0.000525	0.00302	CbGeAlD
Bosutinib—BCR—adrenal gland—adrenal gland cancer	0.000523	0.00301	CbGeAlD
Bosutinib—NUAK2—adrenal gland—adrenal gland cancer	0.000523	0.00301	CbGeAlD
Bosutinib—CSNK1E—pituitary gland—adrenal gland cancer	0.00052	0.003	CbGeAlD
Bosutinib—EPHA4—gonad—adrenal gland cancer	0.00052	0.003	CbGeAlD
Bosutinib—EPHA4—cardiac atrium—adrenal gland cancer	0.000519	0.00299	CbGeAlD
Bosutinib—MAP3K12—adrenal gland—adrenal gland cancer	0.000519	0.00299	CbGeAlD
Bosutinib—MAP2K2—gonad—adrenal gland cancer	0.000514	0.00296	CbGeAlD
Bosutinib—ULK3—gonad—adrenal gland cancer	0.000514	0.00296	CbGeAlD
Bosutinib—MAP2K2—cardiac atrium—adrenal gland cancer	0.000513	0.00296	CbGeAlD
Bosutinib—ULK3—cardiac atrium—adrenal gland cancer	0.000513	0.00296	CbGeAlD
Bosutinib—SIK1—pituitary gland—adrenal gland cancer	0.000512	0.00295	CbGeAlD
Bosutinib—IRAK4—pituitary gland—adrenal gland cancer	0.000512	0.00295	CbGeAlD
Bosutinib—MAP3K2—gonad—adrenal gland cancer	0.00051	0.00294	CbGeAlD
Bosutinib—MAP2K1—adrenal gland—adrenal gland cancer	0.000508	0.00293	CbGeAlD
Bosutinib—STK35—adrenal gland—adrenal gland cancer	0.000508	0.00293	CbGeAlD
Bosutinib—EPHA4—pituitary gland—adrenal gland cancer	0.000507	0.00292	CbGeAlD
Bosutinib—CSK—adrenal gland—adrenal gland cancer	0.000505	0.00291	CbGeAlD
Bosutinib—MAP3K7—cardiac atrium—adrenal gland cancer	0.000504	0.00291	CbGeAlD
Bosutinib—CSNK1A1—adrenal gland—adrenal gland cancer	0.000502	0.00289	CbGeAlD
Bosutinib—MAP2K2—pituitary gland—adrenal gland cancer	0.000501	0.00289	CbGeAlD
Bosutinib—ULK3—pituitary gland—adrenal gland cancer	0.000501	0.00289	CbGeAlD
Bosutinib—TBK1—gonad—adrenal gland cancer	0.000499	0.00288	CbGeAlD
Bosutinib—PTK2—gonad—adrenal gland cancer	0.000499	0.00288	CbGeAlD
Bosutinib—TBK1—cardiac atrium—adrenal gland cancer	0.000499	0.00287	CbGeAlD
Bosutinib—HCK—adrenal gland—adrenal gland cancer	0.000499	0.00287	CbGeAlD
Bosutinib—CLK1—adrenal gland—adrenal gland cancer	0.000499	0.00287	CbGeAlD
Bosutinib—ABL2—adrenal gland—adrenal gland cancer	0.000495	0.00285	CbGeAlD
Bosutinib—MAP3K7—pituitary gland—adrenal gland cancer	0.000493	0.00284	CbGeAlD
Bosutinib—BMP2K—adrenal gland—adrenal gland cancer	0.000489	0.00282	CbGeAlD
Bosutinib—CAMK2G—adrenal gland—adrenal gland cancer	0.000489	0.00282	CbGeAlD
Bosutinib—PTK2—pituitary gland—adrenal gland cancer	0.000487	0.00281	CbGeAlD
Bosutinib—TBK1—pituitary gland—adrenal gland cancer	0.000487	0.00281	CbGeAlD
Bosutinib—LRRK2—adrenal gland—adrenal gland cancer	0.000485	0.00279	CbGeAlD
Bosutinib—YES1—adrenal cortex—adrenal gland cancer	0.000485	0.00279	CbGeAlD
Bosutinib—EGFR—adrenal gland—adrenal gland cancer	0.000484	0.00279	CbGeAlD
Bosutinib—RPS6KB1—cardiac atrium—adrenal gland cancer	0.00048	0.00276	CbGeAlD
Bosutinib—TAOK3—adrenal cortex—adrenal gland cancer	0.000479	0.00276	CbGeAlD
Bosutinib—AXL—gonad—adrenal gland cancer	0.000476	0.00274	CbGeAlD
Bosutinib—AXL—cardiac atrium—adrenal gland cancer	0.000475	0.00274	CbGeAlD
Bosutinib—PTK2B—adrenal gland—adrenal gland cancer	0.000473	0.00272	CbGeAlD
Bosutinib—RPS6KB1—pituitary gland—adrenal gland cancer	0.000469	0.0027	CbGeAlD
Bosutinib—FGR—pituitary gland—adrenal gland cancer	0.000466	0.00268	CbGeAlD
Bosutinib—CSNK1E—adrenal gland—adrenal gland cancer	0.000465	0.00268	CbGeAlD
Bosutinib—AXL—pituitary gland—adrenal gland cancer	0.000464	0.00267	CbGeAlD
Bosutinib—IRAK4—adrenal gland—adrenal gland cancer	0.000458	0.00264	CbGeAlD
Bosutinib—SIK1—adrenal gland—adrenal gland cancer	0.000458	0.00264	CbGeAlD
Bosutinib—SLK—cardiac atrium—adrenal gland cancer	0.000457	0.00263	CbGeAlD
Bosutinib—EPHB4—cardiac atrium—adrenal gland cancer	0.000454	0.00261	CbGeAlD
Bosutinib—EPHA4—adrenal gland—adrenal gland cancer	0.000453	0.00261	CbGeAlD
Bosutinib—ULK3—adrenal gland—adrenal gland cancer	0.000448	0.00258	CbGeAlD
Bosutinib—MAP2K2—adrenal gland—adrenal gland cancer	0.000448	0.00258	CbGeAlD
Bosutinib—SLK—pituitary gland—adrenal gland cancer	0.000447	0.00257	CbGeAlD
Bosutinib—EPHA2—cardiac atrium—adrenal gland cancer	0.000445	0.00257	CbGeAlD
Bosutinib—FYN—cardiac atrium—adrenal gland cancer	0.000444	0.00256	CbGeAlD
Bosutinib—MAP3K2—adrenal gland—adrenal gland cancer	0.000444	0.00256	CbGeAlD
Bosutinib—EPHB4—pituitary gland—adrenal gland cancer	0.000443	0.00255	CbGeAlD
Bosutinib—MAP3K7—adrenal gland—adrenal gland cancer	0.00044	0.00254	CbGeAlD
Bosutinib—TBK1—adrenal gland—adrenal gland cancer	0.000435	0.00251	CbGeAlD
Bosutinib—PTK2—adrenal gland—adrenal gland cancer	0.000435	0.00251	CbGeAlD
Bosutinib—EPHA2—pituitary gland—adrenal gland cancer	0.000435	0.00251	CbGeAlD
Bosutinib—MAP4K5—gonad—adrenal gland cancer	0.000435	0.00251	CbGeAlD
Bosutinib—MAP3K3—gonad—adrenal gland cancer	0.000435	0.00251	CbGeAlD
Bosutinib—MAP3K3—cardiac atrium—adrenal gland cancer	0.000434	0.0025	CbGeAlD
Bosutinib—MAP4K5—cardiac atrium—adrenal gland cancer	0.000434	0.0025	CbGeAlD
Bosutinib—FYN—pituitary gland—adrenal gland cancer	0.000434	0.0025	CbGeAlD
Bosutinib—MAP2K5—adrenal cortex—adrenal gland cancer	0.000429	0.00247	CbGeAlD
Bosutinib—IRAK1—adrenal gland—adrenal gland cancer	0.000427	0.00246	CbGeAlD
Bosutinib—MAP4K5—pituitary gland—adrenal gland cancer	0.000424	0.00244	CbGeAlD
Bosutinib—MAP3K3—pituitary gland—adrenal gland cancer	0.000424	0.00244	CbGeAlD
Bosutinib—CSF1R—adrenal cortex—adrenal gland cancer	0.000419	0.00241	CbGeAlD
Bosutinib—RPS6KB1—adrenal gland—adrenal gland cancer	0.000419	0.00241	CbGeAlD
Bosutinib—FGR—adrenal gland—adrenal gland cancer	0.000416	0.0024	CbGeAlD
Bosutinib—LCK—adrenal gland—adrenal gland cancer	0.000416	0.0024	CbGeAlD
Bosutinib—AXL—adrenal gland—adrenal gland cancer	0.000414	0.00239	CbGeAlD
Bosutinib—YES1—gonad—adrenal gland cancer	0.000402	0.00231	CbGeAlD
Bosutinib—YES1—cardiac atrium—adrenal gland cancer	0.000401	0.00231	CbGeAlD
Bosutinib—SLK—adrenal gland—adrenal gland cancer	0.000399	0.0023	CbGeAlD
Bosutinib—STK10—gonad—adrenal gland cancer	0.000398	0.00229	CbGeAlD
Bosutinib—EPHB4—adrenal gland—adrenal gland cancer	0.000396	0.00228	CbGeAlD
Bosutinib—TAOK3—cardiac atrium—adrenal gland cancer	0.000396	0.00228	CbGeAlD
Bosutinib—YES1—pituitary gland—adrenal gland cancer	0.000392	0.00226	CbGeAlD
Bosutinib—EPHA2—adrenal gland—adrenal gland cancer	0.000389	0.00224	CbGeAlD
Bosutinib—FYN—adrenal gland—adrenal gland cancer	0.000388	0.00223	CbGeAlD
Bosutinib—TAOK3—pituitary gland—adrenal gland cancer	0.000387	0.00223	CbGeAlD
Bosutinib—SRC—gonad—adrenal gland cancer	0.000386	0.00223	CbGeAlD
Bosutinib—SRC—cardiac atrium—adrenal gland cancer	0.000386	0.00222	CbGeAlD
Bosutinib—MAP4K5—adrenal gland—adrenal gland cancer	0.000379	0.00218	CbGeAlD
Bosutinib—MAP3K3—adrenal gland—adrenal gland cancer	0.000379	0.00218	CbGeAlD
Bosutinib—PDGFRB—adrenal cortex—adrenal gland cancer	0.000371	0.00214	CbGeAlD
Bosutinib—MAP2K5—cardiac atrium—adrenal gland cancer	0.000355	0.00205	CbGeAlD
Bosutinib—YES1—adrenal gland—adrenal gland cancer	0.00035	0.00202	CbGeAlD
Bosutinib—STK10—adrenal gland—adrenal gland cancer	0.000347	0.002	CbGeAlD
Bosutinib—CSF1R—gonad—adrenal gland cancer	0.000347	0.002	CbGeAlD
Bosutinib—MAP2K5—pituitary gland—adrenal gland cancer	0.000347	0.002	CbGeAlD
Bosutinib—CSF1R—cardiac atrium—adrenal gland cancer	0.000346	0.002	CbGeAlD
Bosutinib—TAOK3—adrenal gland—adrenal gland cancer	0.000346	0.00199	CbGeAlD
Bosutinib—CSF1R—pituitary gland—adrenal gland cancer	0.000338	0.00195	CbGeAlD
Bosutinib—SRC—adrenal gland—adrenal gland cancer	0.000337	0.00194	CbGeAlD
Bosutinib—ABL1—adrenal cortex—adrenal gland cancer	0.000331	0.00191	CbGeAlD
Bosutinib—MAP2K5—adrenal gland—adrenal gland cancer	0.00031	0.00178	CbGeAlD
Bosutinib—PDGFRB—gonad—adrenal gland cancer	0.000308	0.00177	CbGeAlD
Bosutinib—PDGFRB—cardiac atrium—adrenal gland cancer	0.000307	0.00177	CbGeAlD
Bosutinib—CSF1R—adrenal gland—adrenal gland cancer	0.000302	0.00174	CbGeAlD
Bosutinib—PDGFRB—pituitary gland—adrenal gland cancer	0.0003	0.00173	CbGeAlD
Bosutinib—ABL1—gonad—adrenal gland cancer	0.000274	0.00158	CbGeAlD
Bosutinib—ABL1—cardiac atrium—adrenal gland cancer	0.000274	0.00158	CbGeAlD
Bosutinib—PDGFRB—adrenal gland—adrenal gland cancer	0.000268	0.00154	CbGeAlD
Bosutinib—ABL1—pituitary gland—adrenal gland cancer	0.000268	0.00154	CbGeAlD
Bosutinib—ABL1—adrenal gland—adrenal gland cancer	0.000239	0.00138	CbGeAlD
Bosutinib—ABCB1—adrenal cortex—adrenal gland cancer	0.000103	0.000593	CbGeAlD
Bosutinib—ABCB1—gonad—adrenal gland cancer	8.53e-05	0.000491	CbGeAlD
Bosutinib—ABCB1—pituitary gland—adrenal gland cancer	8.32e-05	0.000479	CbGeAlD
Bosutinib—ABCB1—adrenal gland—adrenal gland cancer	7.43e-05	0.000428	CbGeAlD
Bosutinib—LYN—Signaling Pathways—CDC42—adrenal gland cancer	5.72e-06	2.1e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—CTNNB1—adrenal gland cancer	5.72e-06	2.1e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—EGFR—adrenal gland cancer	5.65e-06	2.08e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CDC42—adrenal gland cancer	5.63e-06	2.07e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IGF2—adrenal gland cancer	5.63e-06	2.07e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—POMC—adrenal gland cancer	5.62e-06	2.07e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—BAD—adrenal gland cancer	5.61e-06	2.07e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CDC42—adrenal gland cancer	5.6e-06	2.06e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—GNAS—adrenal gland cancer	5.58e-06	2.05e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—BAD—adrenal gland cancer	5.58e-06	2.05e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IGF1R—adrenal gland cancer	5.58e-06	2.05e-05	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—EGFR—adrenal gland cancer	5.58e-06	2.05e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—TERT—adrenal gland cancer	5.58e-06	2.05e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—BRAF—adrenal gland cancer	5.55e-06	2.04e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PRKACA—adrenal gland cancer	5.53e-06	2.03e-05	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—EGFR—adrenal gland cancer	5.53e-06	2.03e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—CTNNB1—adrenal gland cancer	5.53e-06	2.03e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IGF2—adrenal gland cancer	5.52e-06	2.03e-05	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—EGFR—adrenal gland cancer	5.5e-06	2.02e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—EGFR—adrenal gland cancer	5.5e-06	2.02e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TERT—adrenal gland cancer	5.5e-06	2.02e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—EGFR—adrenal gland cancer	5.47e-06	2.01e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—GNAS—adrenal gland cancer	5.47e-06	2.01e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—CTNNB1—adrenal gland cancer	5.45e-06	2e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IGF1R—adrenal gland cancer	5.45e-06	2e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—EGFR—adrenal gland cancer	5.44e-06	2e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—BRAF—adrenal gland cancer	5.43e-06	2e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—BAD—adrenal gland cancer	5.43e-06	2e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IGF2—adrenal gland cancer	5.43e-06	2e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—EGFR—adrenal gland cancer	5.42e-06	1.99e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—EGFR—adrenal gland cancer	5.41e-06	1.99e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IGF2—adrenal gland cancer	5.4e-06	1.99e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—GNAS—adrenal gland cancer	5.38e-06	1.98e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—TERT—adrenal gland cancer	5.37e-06	1.98e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—EGFR—adrenal gland cancer	5.37e-06	1.97e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—BAD—adrenal gland cancer	5.36e-06	1.97e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—GNAS—adrenal gland cancer	5.35e-06	1.97e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—EGFR—adrenal gland cancer	5.35e-06	1.97e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IGF1R—adrenal gland cancer	5.33e-06	1.96e-05	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—EGFR—adrenal gland cancer	5.31e-06	1.95e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—BRAF—adrenal gland cancer	5.3e-06	1.95e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—POMC—adrenal gland cancer	5.3e-06	1.95e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—CTNNB1—adrenal gland cancer	5.27e-06	1.94e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—EGFR—adrenal gland cancer	5.26e-06	1.94e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—BAD—adrenal gland cancer	5.25e-06	1.93e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IGF1R—adrenal gland cancer	5.25e-06	1.93e-05	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—EGFR—adrenal gland cancer	5.23e-06	1.92e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IGF1R—adrenal gland cancer	5.22e-06	1.92e-05	CbGpPWpGaD
Bosutinib—FES—Signaling Pathways—TP53—adrenal gland cancer	5.2e-06	1.91e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—CTNNB1—adrenal gland cancer	5.17e-06	1.9e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—EGFR—adrenal gland cancer	5.17e-06	1.9e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—EGFR—adrenal gland cancer	5.17e-06	1.9e-05	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—TP53—adrenal gland cancer	5.16e-06	1.9e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—EGFR—adrenal gland cancer	5.15e-06	1.89e-05	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—TP53—adrenal gland cancer	5.13e-06	1.89e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—BRAF—adrenal gland cancer	5.11e-06	1.88e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—BRAF—adrenal gland cancer	5.08e-06	1.87e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—BAD—adrenal gland cancer	5.08e-06	1.87e-05	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—TP53—adrenal gland cancer	5.08e-06	1.87e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—CTNNB1—adrenal gland cancer	5.06e-06	1.86e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—BAD—adrenal gland cancer	5.06e-06	1.86e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—POMC—adrenal gland cancer	5.01e-06	1.84e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—EGFR—adrenal gland cancer	4.99e-06	1.84e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—BRAF—adrenal gland cancer	4.94e-06	1.82e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—POMC—adrenal gland cancer	4.94e-06	1.82e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—EGFR—adrenal gland cancer	4.92e-06	1.81e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PRKACA—adrenal gland cancer	4.9e-06	1.8e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—BRAF—adrenal gland cancer	4.88e-06	1.79e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—CTNNB1—adrenal gland cancer	4.87e-06	1.79e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDC42—adrenal gland cancer	4.87e-06	1.79e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—BAD—adrenal gland cancer	4.85e-06	1.78e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	4.83e-06	1.77e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TERT—adrenal gland cancer	4.8e-06	1.77e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—BAD—adrenal gland cancer	4.78e-06	1.76e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—TERT—adrenal gland cancer	4.76e-06	1.75e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MED12—adrenal gland cancer	4.75e-06	1.75e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IGF2—adrenal gland cancer	4.69e-06	1.73e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDC42—adrenal gland cancer	4.69e-06	1.73e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TERT—adrenal gland cancer	4.69e-06	1.72e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—POMC—adrenal gland cancer	4.68e-06	1.72e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—BAD—adrenal gland cancer	4.67e-06	1.72e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—GNAS—adrenal gland cancer	4.65e-06	1.71e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—BRAF—adrenal gland cancer	4.62e-06	1.7e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TERT—adrenal gland cancer	4.59e-06	1.69e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—CTNNB1—adrenal gland cancer	4.55e-06	1.67e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—EGFR—adrenal gland cancer	4.54e-06	1.67e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—EGFR—adrenal gland cancer	4.54e-06	1.67e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IGF1R—adrenal gland cancer	4.54e-06	1.67e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—EGFR—adrenal gland cancer	4.53e-06	1.67e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IGF2—adrenal gland cancer	4.52e-06	1.66e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TERT—adrenal gland cancer	4.52e-06	1.66e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TERT—adrenal gland cancer	4.5e-06	1.65e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—CTNNB1—adrenal gland cancer	4.49e-06	1.65e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—BAD—adrenal gland cancer	4.48e-06	1.65e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—GNAS—adrenal gland cancer	4.48e-06	1.65e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—TP53—adrenal gland cancer	4.42e-06	1.63e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—BRAF—adrenal gland cancer	4.42e-06	1.62e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—POMC—adrenal gland cancer	4.41e-06	1.62e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—PTGS2—adrenal gland cancer	4.39e-06	1.61e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—EGFR—adrenal gland cancer	4.38e-06	1.61e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IGF1R—adrenal gland cancer	4.37e-06	1.61e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—BRAF—adrenal gland cancer	4.35e-06	1.6e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—EGFR—adrenal gland cancer	4.35e-06	1.6e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—TP53—adrenal gland cancer	4.34e-06	1.6e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—TP53—adrenal gland cancer	4.34e-06	1.6e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—CTNNB1—adrenal gland cancer	4.32e-06	1.59e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—EGFR—adrenal gland cancer	4.32e-06	1.59e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—PTGS2—adrenal gland cancer	4.28e-06	1.58e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—BRAF—adrenal gland cancer	4.26e-06	1.57e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—CTNNB1—adrenal gland cancer	4.25e-06	1.56e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—TP53—adrenal gland cancer	4.23e-06	1.55e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—TP53—adrenal gland cancer	4.19e-06	1.54e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—BAD—adrenal gland cancer	4.18e-06	1.54e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—EGFR—adrenal gland cancer	4.17e-06	1.54e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—CTNNB1—adrenal gland cancer	4.16e-06	1.53e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—CTNNB1—adrenal gland cancer	4.16e-06	1.53e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDC42—adrenal gland cancer	4.15e-06	1.53e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—CTNNB1—adrenal gland cancer	4.15e-06	1.53e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—BAD—adrenal gland cancer	4.14e-06	1.52e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—PTGS2—adrenal gland cancer	4.13e-06	1.52e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PTGS2—adrenal gland cancer	4.11e-06	1.51e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—EGFR—adrenal gland cancer	4.1e-06	1.51e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—BAD—adrenal gland cancer	4.08e-06	1.5e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—CTNNB1—adrenal gland cancer	4.06e-06	1.49e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CTNNB1—adrenal gland cancer	4.05e-06	1.49e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—CTNNB1—adrenal gland cancer	4.01e-06	1.48e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—EGFR—adrenal gland cancer	4.01e-06	1.48e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IGF2—adrenal gland cancer	4e-06	1.47e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—CTNNB1—adrenal gland cancer	4e-06	1.47e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—BAD—adrenal gland cancer	3.99e-06	1.47e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CTNNB1—adrenal gland cancer	3.98e-06	1.46e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—GNAS—adrenal gland cancer	3.97e-06	1.46e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—BAD—adrenal gland cancer	3.93e-06	1.45e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—CTNNB1—adrenal gland cancer	3.93e-06	1.44e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—RRM1—adrenal gland cancer	3.92e-06	1.44e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SDHD—adrenal gland cancer	3.92e-06	1.44e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—BAD—adrenal gland cancer	3.91e-06	1.44e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TERT—adrenal gland cancer	3.9e-06	1.44e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IGF1R—adrenal gland cancer	3.87e-06	1.42e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—EGFR—adrenal gland cancer	3.86e-06	1.42e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—POMC—adrenal gland cancer	3.85e-06	1.42e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—EGFR—adrenal gland cancer	3.85e-06	1.42e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—CTNNB1—adrenal gland cancer	3.83e-06	1.41e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—BRAF—adrenal gland cancer	3.81e-06	1.4e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—BRAF—adrenal gland cancer	3.77e-06	1.39e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TERT—adrenal gland cancer	3.76e-06	1.38e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—POMC—adrenal gland cancer	3.76e-06	1.38e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TP53—adrenal gland cancer	3.74e-06	1.38e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—BRAF—adrenal gland cancer	3.71e-06	1.37e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—CTNNB1—adrenal gland cancer	3.69e-06	1.36e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—EGFR—adrenal gland cancer	3.69e-06	1.36e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—POMC—adrenal gland cancer	3.68e-06	1.35e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—CTNNB1—adrenal gland cancer	3.67e-06	1.35e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—BRAF—adrenal gland cancer	3.64e-06	1.34e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—POMC—adrenal gland cancer	3.62e-06	1.33e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—EGFR—adrenal gland cancer	3.61e-06	1.33e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—POMC—adrenal gland cancer	3.61e-06	1.33e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—BRAF—adrenal gland cancer	3.58e-06	1.32e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CTNNB1—adrenal gland cancer	3.57e-06	1.31e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—PTGS2—adrenal gland cancer	3.57e-06	1.31e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—BRAF—adrenal gland cancer	3.56e-06	1.31e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—EGFR—adrenal gland cancer	3.56e-06	1.31e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CTNNB1—adrenal gland cancer	3.52e-06	1.3e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—adrenal gland cancer	3.5e-06	1.29e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PRKACA—adrenal gland cancer	3.46e-06	1.27e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CTNNB1—adrenal gland cancer	3.46e-06	1.27e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—EGFR—adrenal gland cancer	3.45e-06	1.27e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—PTGS2—adrenal gland cancer	3.44e-06	1.26e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—EGFR—adrenal gland cancer	3.42e-06	1.26e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—BAD—adrenal gland cancer	3.4e-06	1.25e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—EGFR—adrenal gland cancer	3.37e-06	1.24e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CTNNB1—adrenal gland cancer	3.34e-06	1.23e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TERT—adrenal gland cancer	3.33e-06	1.23e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CTNNB1—adrenal gland cancer	3.33e-06	1.23e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—EGFR—adrenal gland cancer	3.3e-06	1.21e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—EGFR—adrenal gland cancer	3.3e-06	1.21e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—EGFR—adrenal gland cancer	3.29e-06	1.21e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—BAD—adrenal gland cancer	3.27e-06	1.2e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—EGFR—adrenal gland cancer	3.22e-06	1.18e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—EGFR—adrenal gland cancer	3.2e-06	1.18e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—CTNNB1—adrenal gland cancer	3.19e-06	1.17e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—EGFR—adrenal gland cancer	3.18e-06	1.17e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—EGFR—adrenal gland cancer	3.17e-06	1.17e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—EGFR—adrenal gland cancer	3.15e-06	1.16e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CTNNB1—adrenal gland cancer	3.15e-06	1.16e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—POMC—adrenal gland cancer	3.13e-06	1.15e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—EGFR—adrenal gland cancer	3.11e-06	1.14e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—BRAF—adrenal gland cancer	3.09e-06	1.14e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—CTNNB1—adrenal gland cancer	3.08e-06	1.13e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—PTGS2—adrenal gland cancer	3.04e-06	1.12e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—EGFR—adrenal gland cancer	3.04e-06	1.12e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—adrenal gland cancer	3.03e-06	1.11e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—POMC—adrenal gland cancer	3.02e-06	1.11e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—adrenal gland cancer	2.99e-06	1.1e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—BRAF—adrenal gland cancer	2.98e-06	1.1e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CTNNB1—adrenal gland cancer	2.95e-06	1.08e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—EGFR—adrenal gland cancer	2.93e-06	1.08e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MED12—adrenal gland cancer	2.93e-06	1.08e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EGFR—adrenal gland cancer	2.91e-06	1.07e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—BAD—adrenal gland cancer	2.9e-06	1.07e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—adrenal gland cancer	2.88e-06	1.06e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EGFR—adrenal gland cancer	2.83e-06	1.04e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GNAS—adrenal gland cancer	2.81e-06	1.03e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EGFR—adrenal gland cancer	2.79e-06	1.03e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—adrenal gland cancer	2.77e-06	1.02e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—adrenal gland cancer	2.77e-06	1.02e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CTNNB1—adrenal gland cancer	2.75e-06	1.01e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—CTNNB1—adrenal gland cancer	2.72e-06	1e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CTNNB1—adrenal gland cancer	2.68e-06	9.87e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—POMC—adrenal gland cancer	2.67e-06	9.83e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—adrenal gland cancer	2.67e-06	9.82e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—adrenal gland cancer	2.65e-06	9.74e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—adrenal gland cancer	2.64e-06	9.71e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—BRAF—adrenal gland cancer	2.64e-06	9.7e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CTNNB1—adrenal gland cancer	2.63e-06	9.66e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CTNNB1—adrenal gland cancer	2.59e-06	9.51e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CTNNB1—adrenal gland cancer	2.57e-06	9.46e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—adrenal gland cancer	2.49e-06	9.17e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—adrenal gland cancer	2.44e-06	8.96e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—adrenal gland cancer	2.38e-06	8.74e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—adrenal gland cancer	2.34e-06	8.62e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—adrenal gland cancer	2.34e-06	8.59e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CTNNB1—adrenal gland cancer	2.23e-06	8.22e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—adrenal gland cancer	2.22e-06	8.18e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—adrenal gland cancer	2.18e-06	8.01e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—adrenal gland cancer	2.16e-06	7.93e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CTNNB1—adrenal gland cancer	2.15e-06	7.92e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	2.13e-06	7.85e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—adrenal gland cancer	2.13e-06	7.82e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—adrenal gland cancer	2.09e-06	7.7e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—adrenal gland cancer	2.08e-06	7.66e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—adrenal gland cancer	2.05e-06	7.54e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—adrenal gland cancer	2.04e-06	7.5e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CTNNB1—adrenal gland cancer	1.91e-06	7.01e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—POMC—adrenal gland cancer	1.89e-06	6.95e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—adrenal gland cancer	1.83e-06	6.73e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—adrenal gland cancer	1.79e-06	6.57e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—adrenal gland cancer	1.75e-06	6.43e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GNAS—adrenal gland cancer	1.73e-06	6.36e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—adrenal gland cancer	1.72e-06	6.33e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—adrenal gland cancer	1.71e-06	6.3e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—adrenal gland cancer	1.71e-06	6.28e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	1.7e-06	6.24e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—adrenal gland cancer	1.51e-06	5.56e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—adrenal gland cancer	1.51e-06	5.55e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—adrenal gland cancer	1.49e-06	5.47e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—adrenal gland cancer	1.43e-06	5.27e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—adrenal gland cancer	1.27e-06	4.66e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—POMC—adrenal gland cancer	1.16e-06	4.28e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	9.29e-07	3.42e-06	CbGpPWpGaD
